The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study.
Fausto Roila
Consultant or Advisory Role - GlaxoSmithKline; Helsinn Therapeutics; Merck Sharp & Dohme
Honoraria - GlaxoSmithKline; Italfarmaco; Merck Sharp & Dohme
Research Funding - GlaxoSmithKline; Merck Sharp & Dohme
Enzo Ballatori
No relevant relationships to disclose
Benedetta Ruggeri
No relevant relationships to disclose
Sonia Fatigoni
Consultant or Advisory Role - Norgine; Prostrakan
Aurora Mirabile
No relevant relationships to disclose
Barbara Frau
No relevant relationships to disclose
Luigi Cavanna
No relevant relationships to disclose
Sergio Fava
No relevant relationships to disclose
Ida Colantonio
No relevant relationships to disclose
Lucia Angelelli
No relevant relationships to disclose
Libero Ciuffreda
No relevant relationships to disclose
Stefania Eufemia Lutrino
No relevant relationships to disclose
Filippo Zerilli
No relevant relationships to disclose